INmune Bio (NASDAQ:INMB) Releases Quarterly Earnings Results, Misses Estimates By $0.11 EPS

INmune Bio (NASDAQ:INMB - Get Free Report) posted its quarterly earnings results on Thursday. The company reported ($0.60) earnings per share for the quarter, missing analysts' consensus estimates of ($0.49) by ($0.11), Zacks reports. INmune Bio had a negative return on equity of 121.57% and a negative net margin of 26,333.59%. During the same quarter last year, the business earned ($0.48) EPS.

INmune Bio Stock Performance

Shares of INmune Bio stock traded up $0.19 on Friday, reaching $6.04. The company had a trading volume of 225,027 shares, compared to its average volume of 228,751. The firm's 50 day moving average price is $5.64 and its two-hundred day moving average price is $7.77. The firm has a market cap of $119.35 million, a PE ratio of -2.77 and a beta of 1.84. INmune Bio has a 52-week low of $4.78 and a 52-week high of $14.74.

Analyst Ratings Changes

A number of equities analysts have commented on the stock. Raymond James assumed coverage on shares of INmune Bio in a research note on Friday, September 27th. They set an "outperform" rating and a $18.00 target price on the stock. Alliance Global Partners assumed coverage on shares of INmune Bio in a research note on Monday, October 21st. They set a "buy" rating and a $20.00 target price on the stock. Finally, Scotiabank assumed coverage on shares of INmune Bio in a research note on Thursday, August 22nd. They set a "sector outperform" rating and a $22.00 target price on the stock.

Insider Activity

In related news, CEO Raymond Joseph Tesi purchased 15,380 shares of INmune Bio stock in a transaction dated Thursday, September 12th. The shares were acquired at an average cost of $6.38 per share, with a total value of $98,124.40. Following the purchase, the chief executive officer now owns 1,554,106 shares of the company's stock, valued at approximately $9,915,196.28. The trade was a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In related news, CFO David J. Moss purchased 10,000 shares of INmune Bio stock in a transaction dated Monday, September 30th. The shares were acquired at an average cost of $5.29 per share, with a total value of $52,900.00. Following the purchase, the chief financial officer now owns 1,285,869 shares of the company's stock, valued at approximately $6,802,247.01. The trade was a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Raymond Joseph Tesi bought 15,380 shares of the business's stock in a transaction that occurred on Thursday, September 12th. The shares were acquired at an average cost of $6.38 per share, for a total transaction of $98,124.40. Following the completion of the purchase, the chief executive officer now owns 1,554,106 shares in the company, valued at $9,915,196.28. This trade represents a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last three months, insiders have purchased 33,070 shares of company stock valued at $200,087. Company insiders own 35.20% of the company's stock.

INmune Bio Company Profile

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.